EUVIMEDEUVIMED entdecken
Editorial

Risk of perioperative discontinuation of SGLT2 inhibitors

Maartina J P Oosterom-Eijmael, Jeroen Hermanides, Daniel H van Raalte, Abraham H Hulst

British Journal of Anaesthesia · 2024-08 · 133 (2) · 239-240

DOI: 10.1016/j.bja.2024.05.004 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Anaesthesia, 2024-08. Verfasst von Maartina J P Oosterom-Eijmael und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Endocrinology and Metabolism, Amsterdam…. Hauptthemen laut MEDLINE: Heart Failure, Perioperative Care, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When sodium-glucose cotransporter-2 (SGLT2) inhibitors were primarily prescribed for treatment of diabetes mellitus, guidelines recommended withholding SGLT2 inhibitors before surgery to mitigate the associated risk of ketoacidosis. However, currently, SGLT2 inhibitors are an established therapy for patients with heart failure, and there is evidence that withholding SGLT2 inhibitors can worsen these patients' cardiovascular risk profile. We present an updated risk-benefit analysis of withholding SGLT2 inhibitors before surgery, focusing on patients with heart failure and addressing the risk of ketoacidosis and its treatment in these patients. Clinicians should consider perioperative continuation of SGLT2 inhibitors when prescribed for treatment of heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePerioperative CareSodium-Glucose Transporter 2 InhibitorsHumansDiabetes Mellitus, Type 2Diabetic KetoacidosisHypoglycemic AgentsRisk AssessmentWithholding Treatment

Stichwörter der Autor:innen

SGLT2 inhibitoradverse eventseuglycaemic ketoacidosisheart failureperioperative outcome

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Anaesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of…
  • Department of Anaesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. Electronic address: j.hermanides@amsterdamumc.nl.
  • Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands; Amsterdam Ca…
  • Department of Anaesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences Research Institute, Amsterdam, The Netherlands; Amsterdam Gastroenterology Endocrinology…

Zitieren

APA

Oosterom-Eijmael, M. J. P., Hermanides, J., van Raalte, D. H., & Hulst, A. H. (2024). Risk of perioperative discontinuation of SGLT2 inhibitors. British Journal of Anaesthesia, 133(2), 239-240. https://doi.org/10.1016/j.bja.2024.05.004

Vancouver

Oosterom-Eijmael MJP, Hermanides J, van Raalte DH, Hulst AH. Risk of perioperative discontinuation of SGLT2 inhibitors. British Journal of Anaesthesia. 2024;133(2):239-240. doi:10.1016/j.bja.2024.05.004

BibTeX
@article{OosteromEijmael2024,
  author = {Oosterom-Eijmael, Maartina J P and Hermanides, Jeroen and van Raalte, Daniel H and Hulst, Abraham H},
  title = {Risk of perioperative discontinuation of SGLT2 inhibitors},
  journal = {British Journal of Anaesthesia},
  year = {2024},
  volume = {133},
  number = {2},
  pages = {239--240},
  doi = {10.1016/j.bja.2024.05.004}
}
Kostenlos starten →